SEER Inquiry System - Search

Update to current manual/Neoadjuvant therapy/Pathologic tumor size--Breast: When a patient with invasive breast cancer is started on neoadjuvant therapy and at surgery is found to have only residual in-situ disease, do we record the size of the in-situ tumor for Pathologic Tumor Size? See Discussion.

Histology--Soft Tissue:  How is histology coded for malignant neoplasm with neuroectodermal differentiation and TPR-NTRK1 gene rearrangement diagnosed on left shoulder excision? See Discussion.

Reportability/Histology--Kidney: Is an oncocytic renal neoplasm of low malignant potential (ORNLMP) reportable? See Discussion.

Reportability--Ovary: Is an ovarian serous borderline tumor with microinvasion with serous tumor aggregates (3 mm in greatest dimension) in 2 of 10 pelvic lymph nodes reportable? See Discussion.

Reportability--Pancreas: What is the histology code if well differentiated pancreatic endocrine neoplasms (PanNETs) are reportable?

Reportability/Histology--Penis: Are and (PeIN) equivalent to PeIN3 and thus reportable? See Discussion.

Solid Tumor Rules/Histology--Head and Neck, Other Sites: Please provide clarification about effective dates for using p16 testing to assign HPV-related histology codes for various primary sites. See Discussion.

Reportability--Heme & Lymphoid Neoplasms: Is hemophagocytic lymphohistiocytosis synonymous with an EBV-associated lymphoproliferative disorder in children reportable? See Discussion.

Solid Tumor Rules (2018)/Histology--Bladder: Under the Terms that are Not Equivalent or Equal section (Urinary Equivalent Terms and Definitions) it indicates noninvasive is not equivalent to papillary urothelial carcinoma and one should code the histology documented by the pathologist. However, many pathologists use Ta as both the description of the stage and the histology. Should this note be amended? See Discussion.